Cell Cycle

Items 101-150 of 387

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. PLK inhibitor

    NMS-1286937 is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity.
  2. Kras-G12C inhibitor

    KRas G12C inhibitor 2 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
  3. ROCK1/ROCK2 inhibitor

    RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.
  4. IGF-1R, Aurora, FGFR, ABL, SRC inhibitor

    XL228 is a protein kinase inhibitor targeting IGF1R, the AURORA kinases, FGFR1-3, ABL and SRC family kinases. XL228 is an Aurora A inhibitor (IC50, f3 nmol/L) that has shown potent biochemical activity against ABL1 (Ki, 5 nmol/L), as well as the BCR-ABL1 T315I (Ki, 1.4 nmol/L) kinases.
  5. Chk2, KDR, FGFR, Aurora A & Cdk2 inhibitor

    R1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta? FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2.
  6. GGTase inhibitor

    GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that appears to induce apoptosis by downregulating several pivotal oncogenic and tumor survival pathways.
  7. Ras/Raf/MEK inhibitor

    Balamapimod, also known as MKI-822, is a Ras/Raf/MEK inhibitor.
  8. CDK inhibitor

    RGB-286638 is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 and cyclin D3-CDK6.
  9. Ras-Raf interaction inhibitor

    Kobe0065 inhibits anchorage-dependent and -independent growth, blocks MEK/ERK activity and induces apoptosis in H-rasG12V transformed NIH3T3 cells.
  10. CHK1 inhibitor

    CHK1-IN-2 is a checkpoint kinase 1 (CHK1) inhibitor, with an IC50 of 6 nM.
  11. Kras-G12C inhibitor 1

    KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
  12. SOS1 inhibitor

    SOS1-IN-1 is a SOS1 inhibitor.
  13. RAD51 Inhibitor II

    RI-1 is a small molecule that inhibits the central recombination protein RAD51. RI-1 specifically reduces gene conversion in human cells while stimulating single strand annealing. RI-1 binds covalently to the surface of RAD51 protein at cysteine 319 that likely destabilizes an interface used by RAD51 monomers to oligomerize into filaments on DNA.
  14. PLK1 inhibitor

    RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
  15. human A3 adenosine receptor antagonist /Aurora inhibitor

    Reversine is a potent human A3 adenosine receptor antagonist with Ki of 0.66 μM, and a pan-aurora A/B/C kinase inhibitor with IC50 of 12 nM/13 nM/20 nM, respectively. Also used for stem cell dedifferentiation.
  16. Aurora Kinase A Inhibitor

    MK-8745 is a novel Aurora-A specific inhibitor. It induces apoptotic cell death in a p53-dependent manner when tested in vitro in cell lines of multiple lineages.
  17. Cdc42 GTPase inhibitor

    ZCL-278 is a selective inhibitor of Cdc42. Targets the binding site of the Cdc42 guanine nucleotide exchange factor, intersectin (ITSN). Inhibits Cdc42-mediated cellular effects, including microspike formation in 3T3 fibroblasts and neuronal branching in primary neonatal cortical neurons. Also suppresses cell motility and migration in PC3 cells, without cytotoxic effects.
  18. CDK/JAK2/FLT3 inhibitor

    SB1317 is a potent inhibitor of Cyclin dependent kinases (CDKs), FMS-like tyrosine kinase-3 (FLT3) and Janus kinase 2 (JAK2) with IC50 values of 13nM, 56nM and 73nM for CDK2, JAK2 and FLT3, respectively.
  19. CDK inhibitor

    AZD5597 is potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines.
  20. Cdc25 inhibitor

    NSC 663284 is a potent, cell-permeable, and irreversible inhibitor of all Cdc25 isoforms, with preference for Cdc25A (IC50 = 29, 95, and 89 nM for Cdc25A, Cdc25B2, and Cdc25C, respectively).
  21. CDK Inhibitor

    P276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. In Phase 2/3
  22. CDK4/6 inhibitor

    LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
  23. CDK inhibitor

    PHA-690509 is a ATP-competitive CDK inhibitor.
  24. FLT3/CDK inhibitor

    FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.
  25. Aurora kinase A inhibitor

    TC-A-2317 hydrochloride is a potent Aurora kinase A inhibitor (Ki = 1.2 nM compared to 101 nM for inhibition of Aurora kinase B). Selective over 60 other kinases (IC50 values > 1000 nM). Exhibits good cell permeability and antitumor activity.
  26. Chk2 Inhibitor

    BML-277 (Chk2 Inhibitor II) is a Chk2 (checkpoint kinase 2) inhibitor.
  27. ROCK inhibitor

    Glycyl-H 1152 2HCl is a selective and potent ROCK inhibitor (IC50 values are 0.0118, 2.35, 2.57, 3.26, > 10 and >10 uM for ROCKII, Aurora A, CAMKII, PKG, PKA and PKC respectively.)
  28. CDK inhibitor

    BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.
  29. Chk1 inhibitor

    LY2606368 is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity.
  30. Clk inhibitor

    TG003 is a potent, specific, reversible, and ATP competitive inhibitor of Cdc2 like kinase(Clk).-
  31. PDE-KRAS inhibitor

    Deltarasin is a novel small molecule inhibiting the KRAS PDEδ interaction and thus impairing oncogenic KRAS signalling.
  32. c-Myc-Max inhibitor

    10058-F4 is a c-Myc inhibitor that prevents c-Myc/Max dimerization.
  33. ROCK Inhibitor

    HA-1077 inhibits vascular smooth muscle contraction by acting as an intracellular Ca2+ antagonist.
  34. CDK4/6 inhibitor

    PD 0332991 Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM respectively.
  35. BMI-1 inhibitor

    PTC-209 is a novel potent and selective BMI-1 inhibitor, targeting the BMI-1 self-renewal machinery with an IC50 of ~0.5 μM.
  36. Rac family GTPase inhibitor

    EHT 1864 is an antiproliferative chemical shown to inhibit Rac family GTPases.
  37. Rac GTPase inhibitor

    NSC 23766 is a cell-permeable, reversible inhibitor of Rac1 activation by the Rac-specific GEFs TrioN and Tiam 1 (IC50 = 50 uM).
  38. Dual FLT3/CDK4 inhibitor

    AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.
  39. Aurora A/B inhibitor

    SCH-1473759 is a novel sub-nanomolar Aurora A/B inhibitor with IC50 of 4 nM and 13 nM, respectively.
  40. K-Ras(G12C) inhibitor

    K-Ras(G12C) inhibitor 6 is an irreversible inhibitor of oncogenic K-Ras(G12C), subverting the native nucleotide preference to favour GDP over GTP.
  41. ATR/CDK inhibitor

    NU6027 is a potent inhibitor of cellular ATR activity (IC(50)=6.7 μM) and enhanced hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner.
  42. Chk1 inhibitor

    GNE-900 is an ATP-competitive, selective, and orally bioavailable ChK1 inhibitor.
  43. CDK7 Inhibitor

    THZ1 is a novel selective and potent covalent CDK7 inhibitor with IC50(binding affinity) of 3.2 nM; inhibits Jurkat cell's proliferation with IC50 of 50 nM
  44. K-Ras(G12C) inhibitor

    K-Ras(G12C) inhibitor 12 is an allosteric inhibitor of oncogenic K-Ras(G12C).
  45. K-Ras inhibitor

    6H05 is a selective, and allosteric inhibitor of oncogenic K-Ras(G12C).
  46. K-Ras(G12C) inhibitor

    K-Ras(G12C) inhibitor 9 is an allosteric inhibitor of oncogenic K-Ras(G12C).
  47. CDK inhibitor

    LDC000067 is a highly selective CDK9 inhibitor .
  48. BMI-1 inhibitor

    PTC-209 HBr is the hydrobromide salt of PTC-209PTC-209 is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM in HEK293T cell line, and results in irreversible reduction of cancer-initiating cells (CICs).

  49. Clk4 inhibitor

    ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor
  50. DYRK inhibitor

    AZ191 is a potent and selective DYRK1B inhibitor with IC50 of 17 nM, about 5- and 110-fold selectivity over DYRK1A and DYRK2.

Items 101-150 of 387

per page
Set Descending Direction